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Background/Purpose: Surgery followed by postoperative radiotherapy (RT) has been
considered the standard treatment for oral cavity squamous cell carcinoma (OCSCC)
of advanced stages or with adverse prognostic factors. In this study, we compared
the outcomes in patients with OCSCC who received postoperative concurrent
chemoradiotherapy (CCRT) or postoperative RT alone using modern RT techniques.
Methods: A total of 275 patients with OCSCC treated between 2002 and 2018 were
retrospectively analyzed. Adverse prognostic factor was defined as extranodal extension
(ENE), microscopically involved surgical margin, involvement of ≥2 lymph nodes,
perineural disease, and/or lymphovascular invasion (LVI). In total, 148 patients (54%)
received CCRT and 127 patients (46%) received RT alone. More patients in the CCRT
group had N3 disease and stage IVB disease (46.6% vs. 10.2%, p<0.001), ENE (56.1%
vs. 15.7%, p<0.001), LVI (28.4% vs. 13.4%, p=0.033).
Results: With a median follow-up of 40 (range, 5–203) months, there were no significant
differences in the 5-year overall survival (OS) and PFS between treatment groups. In the
subgroup analysis according to high risk, the concurrent use of chemotherapy showed
significantly improved OS in patients with ENE (HR 0.39, p=0.003).
Conclusion: Our retrospective study showed that postoperative CCRT group had
comparable survival outcomes to those in the RT alone group for advanced OCSCC in
the era of modern RT techniques and indicated that concurrent chemotherapy should
be administered to patients with ENE. Prospective randomized studies for confirmation
are needed.
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Squamous cell carcinoma (SCC) is the most common malignancy
of the oral cavity (1). It is estimated that 35,130 people will be
diagnosed with oral cavity cancer in 2019 (2). Surgery followed by
postoperative radiotherapy (PORT) is considered the standard
treatment for oral cavity SCC (OCSCC) of advanced stages or with
adverse prognostic factors. In general, patients with OCSCC tend
to have worse local and regional control compared to other head
and neck subsites (3–5).
Evidence for the concurrent use of chemotherapy was
established by the European Organization for Research and
Treatment of Cancer (EORTC) 22931 and Radiation Therapy
Oncology Group (RTOG) 9501 trials (6, 7). Concurrent
chemotherapy with cisplatin was administrated for high risk
patients and reported that 5-year overall survival (OS) was
approximately 50%.
With advances in radiotherapy (RT) techniques, intensity-
modulated RT (IMRT) has been the standard RT for head and
neck tumors. In this study, we compared the outcomes in
patients with oral cavity SCC (OCSCC) who received
postoperative concurrent chemoradiotherapy (CCRT) or
PORT alone using modern RT techniques.MATERIALS AND METHODS
Study Population
A list of consecutive patients who were diagnosed with OCSCC
and received RT between 2002 and 2018 was extracted from an
institutional cancer registry; a total of 486 patients were
identified. The inclusion criteria were as follows: pathologically
confirmed SCC of oral cavity, resection of primary tumor with/
without neck node dissection, and received postoperative RT
using three-dimensional conformal RT (3D-CRT) or IMRT.
Exclusion criteria were as follows: PORT followed by salvage
resection after recurrence of disease (n = 145); pathologically not
a SCC, such as adenoid cystic carcinoma or sarcoma (n = 41);
palliative treatment due to distant metastasis (n = 21); and
OCSCC with double primary lung cancer (n = 4). After all
exclusions, the data of 275 patients were analyzed.
The procedures followed in this study were in accordance
with the Helsinki Declaration of 1975, as revised in 2000.
This study was approved by our Institutional Review Board
(IRB # 4-2019-0401).
Treatment
Pretreatment evaluation included a complete history, physical
examination and laboratory studies including a complete blood
cell count and serum chemistry profile. Patients underwent
imaging studies such as computed tomography (CT), magnetic
resonance imaging for primary tumor and neck node involvement
evaluation, and positron emission tomography (PET) for
systemic evaluation.
The surgical techniques included resection either by open
approaches or by trans-oral robotic surgery using da Vinci RobotFrontiers in Oncology | www.frontiersin.org 2(Intuitive Surgical Inc., Sunnyvale, CA). Neck dissection was
performed on the involved side or both sides of neck in order to
examine the regional lymph node involvement.
RT was delivered using megavoltage photons (≥6 MV). Using
3D-CRT, a cone-down technique was used. Using IMRT, the
simultaneous integrated boost technique was used in all patients.
The high-risk clinical target volume (CTV)1 encompassed the
primary tumor bed (based on preoperative imaging, physical
examination, and operative findings) and extranodal extension
(ENE) or microscopically involved surgical margin lesions (RM+).
The intermediate-risk CTV2 encompassed the pathologically
positive hemi neck; this frequently required coverage of nodal
levels I, IIa-b, III, and IV for most cases. The low-risk CTV3
usually encompassed the prophylactically treated neck with a low
risk of harboring microscopic disease (e.g., the uninvolved low or
contralateral neck). For the planning target volume (PTV), a 2–5
mm margin was applied to the CTV. The intended total dose for
PTV1 was 60–66 Gy in 2.0 Gy per fraction. If ENE or RM+
were present, the region was treated with 64–66 Gy. The
intended total doses for PTV2 and PTV3 were 60 Gy and 45-
50 Gy, respectively. The target volume was delineated on
simulation CT fused with PET and other images. Helical
tomotherapy (HT), an image-guided IMRT system using
megavoltage CT (MVCT) that provides precise delivery, was
used in IMRT. HT was demonstrated to have better target
volume dose conformity and homogeneity than other IMRT
(8). The daily MVCT images were fused with the original
treatment planning based on soft tissue and bony structures at
each fraction. The position was corrected manually to align
target volume after automatic registration (9).
Concurrent chemotherapy was added to RT in patients with
high risk OCSCC. High risk was defined by ENE, RM+,
perineural invasion (PNI), lymphovascular invasion (LVI),
and/or multiple nodes involvement. ENE was defined as
extension of cancer cells through the lymph node capsule. The
pathological margins were classified as negative (>5 mm), close
(≤5 mm), and positive (presence of cancer cells microscopically
[RM+]). Patients received concurrent chemotherapy as follows:
cisplatin was administered as a weekly dose of 25–40 mg/m2 or a
triweekly dose of 100 mg/m2 from the first day of RT.
Each patient was examined by a dental team for pre-
radiotherapy dental care, which was completed before the
initiation of PORT. In addition to clinical examination,
radiographic examination was performed to determine the
periodontal status and the presence of periapical inflammation
and other dental diseases. Each patient was examined at least
once a week to monitor treatment-related toxicities. Treatment-
related toxicities were graded according to the Common Toxicity
Criteria for Adverse Events version 5.0.
Patterns of first failure were defined as loco-regional failure or
distant metastases. The date of failure was the date of tissue
confirmation or imaging study showing evidence of failure. Local
failure was defined as failure occurring within the same site of the
primary tumor, regional failure if occurring within the regional
lymph nodes, and distant failure if occurring outside of the local
and regional areas.March 2021 | Volume 11 | Article 619372
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Statistical analyses were conducted using IBM SPSS version 25.0
(IBM Corp., Armonk, NY). The differences in characteristics and
toxicities were compared using chi-square tests, and the Kaplan–
Meier method was used to calculate the OS, progression-free
survival (PFS), loco-regional failure-free survival and distant
metastasis-free survival; differences between the curves were
analyzed using the log-rank test. Cox proportional hazards
models were used to assess the association of variables with the
survival and hazard ratio (HR) and confidence interval (CI).
Statistical significance was defined as p < 0.05. Factors showing
p < 0.10 in the univariate analyses were included in the
multivariate analyses.RESULTS
Patient Characteristics
The patient and pathologic characteristics are summarized in
Table 1. The median age of patients was 58 years (range, 18–86)
and the male-to-female ratio was 6:4. The most common primary
site was the oral tongue (54%, n = 148), followed by the buccal
mucosa (13%, n = 37), retromolar trigone (12%, n = 32), and
alveolar ridge (12%, n = 32). The most common pathologic T and
N status were T4 (36%, n = 98) and N3 (30%, n = 82). A total of
119 patients (43%) had stage IVA disease according to American
Joint Committee On Cancer (AJCC) 8th edition and 82 patients
(30%) had stage IVB disease. A total of 103 patients (37%) had
ENE and 72 patients (26%) had RM+.
The characteristics that differed by treatment group included
pathologic N status, AJCC stage, ENE, resection margin status,
RT dose and RT modality. More patients in the CCRT group had
N3 disease and AJCC stage IVB disease (46.6% vs. 10.2%,
p<0.001), ENE (56.1% vs. 15.7%, p<0.001), LVI (28.4% vs.
13.4%, p=0.033). The mean RT dose was higher in the CCRT
group (62.2 Gy vs. 60.9 Gy, p=0.002) and fewer patients received
IMRT (7.4% vs. 19.7%, p=0.004). The other characteristics were
well balanced between treatment groups.
Ipsilateral neck dissection was performed for 268 patients (98%),
of whom 129 (47%) received modified radical neck dissection
(mRND), 121 (44%) received supra-omohyoid neck dissection
(SOND), and 18 (7%) received selective neck dissection (SND).
Contralateral neck dissection was performed for 87 patients (32%),
of whom 10 (4%) received mRND, 58 (21%) received SOND, and
19 (7%) received SND.
A total of 36 patients (13%) received 3D-CRT and 239 patients
(87%) received IMRT. The median RT dose was 63 Gy (range, 50–
67.5), median high risk CTV fractional dose was 2.1 Gy (range, 1.8–
2.5) and median fraction number was 30 (range, 20-36). The
median treatment day of RT was 42 days (range, 32–70) and total
treatment time from surgery to finish of RT was 82 days (range, 63–
177). A total of 148 patients (54%) received concurrent
chemotherapy, three patients received induction chemotherapy
consisting of cisplatin and gimeracil, also known as TS-1, before
surgery, and one patient received maintenance gimeracil
chemotherapy after RT. The median cumulative dose of cisplatinFrontiers in Oncology | www.frontiersin.org 3was 200 mg/m2 (range, 40–300 mg/m2). Most patients (66%,
n = 97) completed chemotherapy without interruption. A total of
17 patients (12%) discontinued concurrent chemotherapy because









Age (median in year) 58 (18-86) 58.5 (18-80) 58.0 (24–86)
Age (year) 0.904
<60 143 (52.0) 76 (51.4) 67 (52.8)
≥60 132 (48.0) 72 (48.6) 60 (47.2)
Sex 0.900
Male 175 (63.6) 95 (64.2) 80 (63.0)
Female 100 (36.4) 53 (35.8) 47 (37.0)
Performance status 0.478
ECOG PS 0–1 256 (93.1) 136 (91.9) 120 (94.5)
ECOG PS 2 19 (6.9) 12 (8.1) 7 (5.5)
Subsite 0.960
Tongue 148 (53.8) 79 (53.4) 69 (54.3)
Buccal mucosa 37 (13.5) 20 (13.5) 17 (13.4)
Retromolar trigone 32 (11.6) 19 (12.8) 13 (10.2)
Gingiva, alveolar
ridge
32 (11.6) 15 (10.1) 17 (13.4)
Floor of mouth 18 (6.5) 11 (7.4) 7 (5.5)




T1 56 (20.4) 24 (16.2) 32 (25.2)
T2 82 (29.8) 43 (29.1) 39 (30.7)
T3 38 (13.8) 20 (13.5) 18 (14.2)




N0 70 (25.5) 20 (13.5) 50 (39.4)
N1 46 (16.7) 19 (12.8) 27 (21.3)
N2 77 (28.0) 40 (27.0) 37 (29.1)
N3 82 (29.8) 69 (46.6) 13 (10.2)
AJCC 8th stage <0.001
I 12 (4.4) 2 (1.4) 10 (7.9)
II 22 (8.0) 5 (3.4) 17 (13.4)
III 40 (14.5) 12 (8.1) 28 (22.0)
IVA 119 (43.3) 60 (40.5) 59 (46.5)
IVB 82 (29.8) 69 (46.6) 13 (10.2)
Extranodal extension <0.001
Yes 103 (37.5) 83 (56.1) 20 (15.7)




Yes 59 (21.5) 42 (28.4) 17 (13.4)
No 216 (78.5) 106 (71.6) 110 (86.6)
Perineural invasion 0.176
Yes 97 (35.3) 63 (42.6) 34 (26.8)
No 178 (64.7) 85 (57.5) 93 (73.2)
Resection margin 0.017
Positive 72 (26.2) 47 (31.8) 25 (19.7)
Close 94 (34.2) 53 (35.8) 41 (32.3)
Negative 109 (39.6) 48 (32.4) 61 (48.0)










3D-CRT 239 (86.9) 137 (92.6) 102 (80.3)
IMRT 36 (13.1) 11 (7.4) 25 (19.7)March 2021 | Volume 11 | ArticleECOG, Eastern Cooperative Oncology Group; AJCC, American Joint Committee on
Cancer; RT, radiotherapy; 3D-CRT, 3-dimensional conformal radiotherapy; IMRT, intensity
modulated radiotherapy.619372
Kim et al. Postoperative Chemoradiotherapy for Oral Cavity Cancerand grade 3 neutropenia (n = 5). Furthermore, the chemotherapy
dose was reduced in 15 (10%) patients because of grade 3 fatigue
(n = 8), and grade 3 neutropenia (n = 7).
Survival Analysis, Prognostic Factors
With a median follow-up of 40 months (range, 5–203), the
5-year OS and PFS rates were 65% and 61%, respectively
(Figure 1). Median OS was not reached, and median PFS was
140 months (95% CI, 67.6–212.4). According to primary site, the
5-year OS were follows: oral tongue (69%), buccal mucosa (64%),
retromolar trigone (55%), gingiva and alveolar ridge (56%), floor
of mouth (76%), hard palate (42%).
The prognostic factors associated with OS are summarized in
Table 2. Univariate analysis revealed that pathologic T and N
status, AJCC stage, ENE, and PNI were significant prognostic
factors associated with OS. In the multivariate analysis,
pathologic T status and PNI were associated with poorer OS.
The prognostic factors associated with PFS are summarized in
Table 3. Univariate analysis revealed that pathologic T and N
status, AJCC stage, ENE, and PNI were significant prognostic
factors associated with PFS. In the multivariate analysis,
pathologic T status and PNI were associated with poorer PFS.
Outcomes According to Treatment Group
There were no significant differences in the 5-year OS (64% vs.
65%, p = 0.974) and PFS (62% vs. 60%, p=0.846) betweenFrontiers in Oncology | www.frontiersin.org 4treatment groups (Figure 2). No significant difference was
observed in the 5-year loco-regional failure-free survival (79%
vs. 77%, p = 0.599) and distant metastasis-free survival (78% vs.
81%, p = 0.475).
In the subgroup analysis according to high risk (ENE, RM+,
PNI, LVI, and multiple node), the concurrent use of
chemotherapy showed significantly improved OS in patients
with ENE (HR 0.39, 95% CI 0.21–0.43, p = 0.003, Figure 3),
while there was no advantage in OS in patients with RM+, PNI,
LVI, and multiple node.
Outcomes According to Indications of
Chemotherapy
In total, 103 and 72 patients had ENE and RM+, respectively; 22
patients had both ENE and RM+ and 153 patients had either
ENE or RM+. Concurrent chemotherapy significantly improved
the 5-year OS in patients with ENE (56% vs. 32%, p = 0.002);
however, it did not improve the 5-year OS in patients with RM+
(64% vs. 64%, p = 0.899). Moreover, concurrent chemotherapy
was not beneficial in patients with either ENE or RM+ (p =
0.116), but it was beneficial in terms of survival in patients with
both ENE and RM+ (p < 0.001). The mean RT dose for patients
with ENE was statistically higher than that for patients without
ENE (62.7 Gy vs. 60.9 Gy, p < 0.001). Similarly, the mean RT
dose for patients with RM+ was statistically higher than that for
patients without RM+ (62.6 Gy vs. 61.2 Gy, p < 0.001).FIGURE 1 | Overall survival and progression free survival.March 2021 | Volume 11 | Article 619372
Kim et al. Postoperative Chemoradiotherapy for Oral Cavity CancerThe most common first pattern of failure in patients with ENE
was distant failure (26%), followed by local (16%) and regional
failures (15%). In patients with RM+, the rates of local (13%),
regional (15%), and distant (13%) failures were similar. The overall
rates of distant failure in patients with ENE, RM+, and negative
resection margins were 32%, 21%, and 16%, respectively.
Patterns of First Failure
Treatment failure occurred in 48 and 59 patients in the RT alone
and CCRT groups, respectively. The patterns of first failure are
summarized in Figure 4. A total of 37 patients (13%) had local
failures, 33 patients (12%) had regional failures, and 37 patients
(13%) had distant failures (Figure 4A). The most common
patterns of failure in CCRT was distant failure (15%) followed
by regional (14%) and local (11%) (Figure 4B), and the most
common patterns of failure in RT alone was local failure (17%),
followed by distant (12%) and regional failures (9%) (Figure 4C).Frontiers in Oncology | www.frontiersin.org 5Toxicity
A total of 105 patients (38.2%) had grade 3 mucositis, and three
patients had grade 3 skin reaction. With respect to late toxicities, 10
patients (3.6%) suffered from osteoradionecrosis (ORN) of the
mandible and five patients had orocutaneous fistula. Among
the 10 patients with ORN, five patients had a primary tumor near
the mandible (one with retromolar trigone and four with gingiva),
five had pathologic T4a disease and eight received more than 60 Gy
of RT. Among the five patients with orocutaneous fistula, all
patients had pathologic T4a disease and received more than 60
Gy, and three had RM+.DISCUSSION
This study reports outcomes for patients with OCSCC treated
with surgery followed by CCRT or RT alone. A total of 239TABLE 3 | Prognostic factors for progression free survival.
Variable Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age (<60 vs. ≥60) 0.930 0.630–1.373 0.715
Sex (Female vs. Male) 0.938 0.621–1.416 0.761
Performance (ECOG PS0–1 vs. PS2) 1.385 0.698–2.747 0.352
T classification (T1–2 vs. T3–4) 1.918 1.287–2.857 0.001 1.881 1.224–2.891 0.004
N classification (N0–1 vs. N2–3) 2.056 1.338–3.159 0.001 1.659 0.925–2.975 0.089
AJCC stage (I–II vs. III–IV) 3.319 1.347–8.180 0.009 1.387 0.495–3.891 0.534
ENE (No vs. Yes) 1.873 1.270–2.762 0.002 1.314 0.791–2.183 0.292
LVI (No vs. Yes) 1.375 0.885–2.137 0.156
PNI (No vs. Yes) 1.683 1.138–2.489 0.009 1.572 1.055–2.342 0.026
RM (Negative vs. Close/Positive) 1.236 0.827–1.849 0.301
Treatment modality (RT alone vs. CCRT) 0.963 0.652–1.421 0.848
RT modality (3D-CRT vs. IMRT) 0.934 0.544–1.603 0.804March 2021 | Volume 11 | ArticleThe foreparts of the parentheses were set as the reference group.
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; AJCC, American Joint Committee on Cancer; ENE, extranodal extension; LVI, lymphovascular
invasion; PNI, perineural invasion; RM, resection margin; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; 3D-CRT, three-dimensional conformal radiation therapy; IMRT,
intensity-modulated radiation therapy.TABLE 2 | Prognostic factors for overall survival.
Variable Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age (<60 vs. ≥60) 1.031 0.673–1.579 0.888
Sex (Female vs. Male) 0.974 0.622–1.525 0.908
Performance (ECOG PS0–1 vs. PS2) 0.857 0.347–2.117 0.739
T classification (T1–2 vs. T3–4) 1.800 1.163–2.786 0.008 1.660 1.043–2.642 0.033
N classification (N0–1 vs. N2–3) 1.972 1.230–3.163 0.005 1.348 0.694–2.615 0.378
AJCC stage (I–II vs. III–IV) 4.372 1.381–13.840 0.012 2.207 0.620–7.852 0.221
ENE (No vs. Yes) 2.065 1.348–3.164 0.001 1.525 0.848–2.740 0.159
LVI (No vs. Yes) 1.511 0.942–2.425 0.087 1.234 0.757–2.012 0.399
PNI (No vs. Yes) 1.868 1.217–2.867 0.004 1.595 1.020–2.495 0.041
RM (Negative vs. Close/Positive) 1.481 0.945–2.322 0.087 1.445 0.916–2.277 0.113
Treatment modality (RT alone vs. CCRT) 0.993 0.648–1.522 0.974
RT modality (3D-CRT vs. IMRT) 0.869 0.494–1.530 0.627The foreparts of the parentheses were set as the reference group.
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; AJCC, American Joint Committee on Cancer; ENE, extranodal extension; LVI, lymphovascular
invasion; PNI, perineural invasion; RM, resection margin; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; 3D-CRT, three-dimensional conformal radiation therapy; IMRT,
intensity-modulated radiation therapy.619372
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up of 40 months, there were no significant differences in the OS
and PFS between treatment groups. Considering the fact that
patients in the CCRT group had more N3 disease, ENE, and LVI,
use of concurrent chemotherapy had beneficial effect on survival
than RT alone.
In the EORTC 22931 and RTOG 9501 trials (6, 7), ENE and/
or RM+ were the most significant prognostic factors, and the
concurrent chemotherapy with PORT appeared to improve the
survival of patients with OCSCC. The 10-year follow-up results
were reported to examine long-term outcomes (6). In the subset
analysis limited to patients with ENE and/or RM+, local-regional
failure rates were 33.1% vs. 21.0% (p=0.02) and the OS was 19.6%Frontiers in Oncology | www.frontiersin.org 6vs. 27.1% (p=0.07). These results demonstrated improved disease
control with concurrent administration of chemotherapy. In our
study, there showed improved survival with concurrent
administration of chemotherapy for patients with ENE (6). In
the subgroup analysis, the mean RT dose for patients with ENE
or RM+ was statistically higher than that for patients without
ENE or RM+. Radiation dose escalation for RM+ could explain
the similar rates of local, regional, and distant failures.
Hsieh C.H. et al. reported that PORT with image guidance
results in better OS and LCR than postoperative RT without
image guidance (10). Patients who received image-guided IMRT
had a better 5-year OS than patients who received non-image-
guided IMRT (87% vs. 48%). In our institution, all the patientsA B
FIGURE 2 | (A) Overall survival stratified by concurrent chemotherapy. (B) Progression free survival stratified by concurrent chemotherapy.FIGURE 3 | Overall survival in treatment groups.March 2021 | Volume 11 | Article 619372
Kim et al. Postoperative Chemoradiotherapy for Oral Cavity Cancerwith head and neck cancer received image-guided HT, and patients
were verified every day withMVCT. In case of weight loss or change
in body shape, we made an adaptive plan for these patients.
According to the report by the Memorial Sloan Kettering
Cancer center (MSKCC), 44 of 1,023 patients (4.3%) developed
ORN. Patients with ORN had poor periodontal status, a history
of heavy alcohol use, and received a higher radiation dose (11).
Patients with oropharyngeal cancer are prone to develop ORN
compared to patients with OCSCC because patients with
oropharyngeal cancer receive a higher radiation dose. Similar
results were observed in our analysis. Among 10 patients with
ORN, most of them received a higher radiation dose and had a
primary tumor near the mandible. In a report of oropharyngeal
cancer from our institution, approximately 30% of patients had
overall grade ≥3 acute toxicities treated with definitive RT (12).
In this study, 38% of patients had grade 3 mucositis in the results
of OCSCC treated with surgery followed by PORT. With respect
to late toxicities, our data showed acceptable results.
Several studies have reported outcomes for specific subsites
within the oral cavity. Wang Ling et al. reported the survival
outcomes of 210 patients with SCC of the tongue (13). The
5-year OS rate for patients who underwent surgery and surgery
with PORT were 58.2% and 45.6%, respectively. PORT wasFrontiers in Oncology | www.frontiersin.org 7performed for stage III-IV patients, while stage I-II patients
received surgery alone. In our data, the 5-year OS for patients
with tongue cancer was 65%. Moreover the MSKCC reported the
results of SCC of the gingivobuccal complex (14). The 5-year OS
rate for patients with tongue (n = 936) and gingivobuccal cancer
(n = 486) were 67.8% and 61%, respectively. PORT was
performed for 40% of tongue cancer patients and 26% of
gingivobuccal cancer patients. Patients with gingivobuccal
cancer were more likely to be older and have more advanced
disease. In our data, the 5-year OS rate was 64% for patients with
buccal mucosa cancer. Nishi H. et al. reported 45 patients with
retromolar trigone cancer and reported a 3-year OS rate of
59.8%, as well as pathologic LN involvement as a prognostic
factor (15). In our data, the 3-year OS rate for patients with
retromolar trigon cancer was 60%. According to a previous
retrospective cohort study using the SEER database
(Surveillance, Epidemiology, and End Results), the 5-year OS
rate for patients with floor of mouth cancer was 40% (16). In our
data, the 5-year OS rate for patients with floor of mouth cancer
was 76%, although only 18 patients had floor of mouth cancer.
The current study has several limitations. There was
heterogeneity of tumor subsites, surgery techniques including
neck dissection methods, and radiation dose and field; theseA B
C
FIGURE 4 | Patterns of first failure (A) All patients, (B) Concurrent chemoradiotherapy, (C) Radiotherapy alone.March 2021 | Volume 11 | Article 619372
Kim et al. Postoperative Chemoradiotherapy for Oral Cavity Cancerdifferences may have influenced the local, regional, and distant
tumor response. Furthermore, after the first failure, the salvage
methods were not uniform. Some patients received re-operation,
chemotherapy only, and/or re-irradiation for recurrent tumor;
this might have influenced the OS. Because this study was
retrospective, the incidence of treatment-related toxicities
could be underestimated. However, the current study evaluated
a large number of patients with OCSCC who received surgery
followed by PORT, and determined the impact of concurrent
chemotherapy. Because the EORTC 22931 and RTOG 9501 trials
(6, 7) included a heterogeneous group of patients, including
those with cancers of the oral cavity, oropharynx, larynx, or
hypopharynx, prospective randomized controlled trials are
needed for OCSCC. This study could be considered as a
preliminary study for such trials. Until such trials have been
reported, the recommendation based on the combined analysis
of EORTC 22931 and RTOG 9501 still need to be followed (7).
In conclusion, our retrospective study showed that
postoperative CCRT group had comparable survival outcomes
to those in the RT alone group for advanced OCSCC in the era of
modern RT techniques and indicated that concurrent
chemotherapy should be administered to patients with ENE.
Prospective randomized studies for confirmation are needed.Frontiers in Oncology | www.frontiersin.org 8DATA AVAILABILITY STATEMENT
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